Swiss double Covid vaccine order from Pfizer/BioNTech
Switzerland has ordered enough to vaccinate the population more than two times over.
Keystone / Fazry Ismail
The Swiss government has signed a new deal with Pfizer/BioNTech for another three million vaccine doses, bringing the total number of doses ordered from five companies to nearly 36 million.
The additional doses will be delivered to Switzerland in April, according to the government. When announcing the “good news”, health minister Alain Berset tweeted that “one million (doses) will already be available in the cantons in April, May and June”.
This comes amid concerns about the slow pace of the vaccine rollout. To date, only 1.3 million doses have been delivered and around 3.8% of the population has been fully vaccinated. As a comparison, in Israel, which has about the same population as Switzerland, more than 40% of the population is fully vaccinated.
During a press conference yesterday, Nora Kronig, deputy director of the Federal Office of Public Health, said vaccinations were still progressing according to plan. “We are still confident that by the end of June we will be able to vaccinate anyone who wants to,” Kronig told reporters.
Spreading its purchases
Switzerland has so far bought more than 35 million doses for its population of 8.6 million. These doses are from five manufacturers: Moderna (13.5 million doses), Pfizer/BioNTech (now around 6 million), Oxford/AstraZeneca (around 5.3 million), Curevac (5 million) and Novavax (6 million).
In a statementExternal link, the government said “given that production and availability of vaccines are subject to such great uncertainty, the federal government continues to look into different vaccine technologies from different vaccine manufacturers”. However, it is focusing on mRNA vaccines because they are “proving to be highly effective and well tolerated”. Four out of the five vaccines ordered are mRNA-based.
So far, only the Pfizer and Moderna vaccines have been approved by the Swiss medical regulator Swissmedic. CureVac and Novavax have not yet filed for approval and Oxford/AstraZeneca’s vaccine is still being reviewed. Swissmedic has said that based on the available data, the safety, efficacy and quality of the vaccine could not be conclusively evaluated. It is still awaiting results of large-scale clinical trials from Oxford/AstraZeneca.
Popular Stories
More
Climate adaptation
Why Switzerland is among the ten fastest-warming countries in the world
This content was published on
Spain ended Switzerland’s run in the Women’s Euros on Friday, but fans in Bern made history with the largest supporters’ march in Women’s Euros history.
This content was published on
Solar energy pioneer Raphaël Domjan and his team continued preparations for the altitude record attempt at 10,000 metres with the SolarStratos solar aircraft.
This content was published on
Cattle in the canton of Geneva and in the neighbouring region of Terre Sainte in the canton of Vaud are being vaccinated against the contagious viral skin nodule disease. The first cases of the animal disease were reported at the end of June in France, just outside Geneva.
Fewer attacks on Swiss ATMs but their future remains uncertain
This content was published on
Bank ATMs in Switzerland are less prone to attacks by criminals, but their future remains uncertain given the less active use of cash by the population.
This content was published on
A series of rockfalls occurred above the village of Brienz between 9 and 12 July. According to the municipality of Albula, the overall situation remains tense. Several people disregarded the ban on entering the area around the village.
This content was published on
Arosa Bergbahnen achieved the highest figure in its 95-year history in the 2024/25 financial year with net revenue of CHF 37 million. Arosa Lenzerheide was able to capitalise on strengths such as snow reliability and the size of the ski area in a long winter season, the company announced on Thursday.
This content was published on
Unknown perpetrators stole ceramic dental implants during a break-in at a company in Oensingen, northern Switzerland, on Tuesday night.
Euro 2025: Bern prepares for massive parade ahead of Switzerland-Spain game
This content was published on
The last Euro 2025 match to be played in Bern, the quarterfinal between Spain and Switzerland at 9pm on Friday, promises to be a great celebration of football.
Clariant faces further ethylene price-fixing claim
This content was published on
Swiss chemicals group Clariant is facing a further claim for damages in connection with ethylene price-fixing agreements.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Covid-19 vaccine: Why we still have a long wait ahead
This content was published on
Countries have started rolling out a Covid-19 vaccine, but it will likely take years to manufacture doses at the scale needed to reach the masses.
This content was published on
Switzerland will be affected by the temporary delay to the Pfizer-BioNTech Covid-19 vaccine in Europe, the Swiss health authorities have confirmed.
Calls intensify for Big Pharma to break monopolies on Covid-19 vaccines
This content was published on
Pressure is mounting to suspend intellectual property rules to help vaccines reach more people. Can the WTO find a solution?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.